• info@heparegenix.com
  • +49 (0)7071 7912810
  • Sitemap
  • Site Notice
  • Privacy Policy
HepaRegeniX GmbH
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact
Search
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact

HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

p3889712022-11-23T10:05:06+01:00

Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.

11/23/2022
By p3889712022, Press releaseComments Off
Read more...

HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor

p3889712022-05-12T10:21:20+02:00

HRX-0215 proved to be safe and well tolerated in healthy volunteers.

05/12/2022
By p3889712022, Press releaseComments Off
Read more...

HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors

p3889712022-03-30T11:52:14+02:00

He follows Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.

03/30/2022
By p3889712022, Press releaseComments Off
Read more...
Get In Touch
HepaRegeniX GmbH: Logo

HepaRegeniX has successfully discovered and developed several drug candidates to combat multiple liver diseases. The first candidate HRX-0215 has recently entered clinical development.

Get in touch

Phone: +49 (0)7071 7912810
Fax: +49 (0)7071 7912809
E-mail: info@heparegenix.com

Address

HepaRegeniX GmbH
Eisenbahnstraße 63
72072 Tübingen
Germany

© Copyright 2016-2020 HepaRegeniX GmbH. All Rights Reserved.